

Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Alberto Ragni¹

¹ Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo

Potential competing interests: Employee of the same hospital of some of the Authors

This manuscript represents an interesting initiative with the aim of evaluating the best options regarding medical treatment of bone metastases from solid tumours. The analysis has an important practical repercussion given that it takes into considerations various practical aspects of the topic, such as drug costs, commitment to both patients and health institutions, etc.

The conclusions reached by the Authors are indeed important and could have a significant impact on everyday clinical practice.

Given the clinical importance of this document, I believe that it is of utmost importance to better clarify the methodology at its base, since the “Methods” section is somewhat partially explained. In particular:

- The Authors should better explain the “PICO” methodology, also by adding a specific reference (i.e.: PMID: 21808439)
- The Authors should insert in the “Methods” section the details of the PICO process, in particular which health databases have been searched (Medline, Pubmed, Web of Science, etc...?)
- A English language review of the manuscript is recommended